Bayer snaps up biotech firm Vividion Therapeutics for $2 billion

Bayer snaps up biotech firm Vividion Therapeutics for $2 billion

By Christy Gren - Aug 05, 2021

Bayer AG is in talks to buy Vividion Therapeutics in a roughly $2 billion deal, enforcing new IPO plans for Vividion.

Read More
Sanofi bets big on mRNA future with Translate Bio acquisition offer

Sanofi bets big on mRNA future with Translate Bio acquisition offer

By Anna Domanska - Aug 03, 2021

Sanofi’s CEO Paul Hudson is dead serious about mRNA technology and capabilities with a $3.2 billion acquisition offer to Translate Bio.

Read More
Bristol Meyer ties up with AI pharmatech Exscientia

Bristol Meyer ties up with AI pharmatech Exscientia

By Christy Gren - May 19, 2021

Bristol-Myers Squibb, the Big Pharma company, has entered into a drug discovery collaboration worth $1.2 billion, with artificial intelligence (AI) pharmatech company, Exscientia.

Read More
Bayer plans 3 new drugs, banks on gene and cell therapy allogeneic cancer medicines

Bayer plans 3 new drugs, banks on gene and cell therapy allogeneic cancer medicines

By Anna Domanska - Jan 13, 2021

German pharma giant Bayer has plans to introduce three news drugs with annual sales potential of $1.22 billion (€1 billion) but these will not offset the fall in revenue the comp

Read More
Latest in M&A: Sanofi snaps up rival Principia Biopharma for $3.36 billion

Latest in M&A: Sanofi snaps up rival Principia Biopharma for $3.36 billion

By Christy Gren - Aug 17, 2020

French healthcare company Sanofi has agreed to acquire U.S. company Principia Biopharma Inc. for around $3.7 billion.

Read More